Interlukin-10, interferon-γ and tumor necrosis factor-α genes variation in prostate cancer and benign prostatic hyperplasia

Current Urology

Volumn 2, Issue 4, 2009, Pages 175-180

  Omrani, Mir D ^a,c   Bazargani, Soroush ^b   Bageri, Morteza ^a  

^a Department of Genetics ^*  (Iran)

^b Uromia Medical Sciences University   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Benign prostatic hyperplasia; IFN ; IL 10; Polymorphism; Prostate cancer; TNF

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77953391094     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000209829     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Glob-al cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR: Evaluation of prostate cancer character-istics in four populations worldwide. Can J Urol2008;15:4056-064.
3. Singh R, Eeles RA, Durocher F, Simard J, Ed-wards S, Badzioch M, Kote-Jarai Z, Teare D, Ford D, Dearnaley D, Ardern-Jones A, Mur-kin A, Dowe A, Shearer R, Kelly J, Labrie F, Easton D, Narod SA, Tonin PN, Foulkes WD: High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis 2000;3:241-247.
4. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE: Risk of cancer in BRCA1 muta-tion carriers. Lancet 1994;343:692-695.
5. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM: Influ-ence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 2002;62:3369-3372.
6. Hrouda D, Perry M, Dalgleish AG: Gene therapy for prostate cancer. Semin Oncol 1999;26:455-471.
7. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, Hardt C, D'Alfonso S: Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 2001;2:61-70.
8. Beecken WD, Kramer W, Jonas D: New mo-lecular mediators in tumor angiogenesis. J Cell Mol Med 2001;4:262-269.
9. Uboldi de Capei M, Dametto E, Fasano ME, Rendine S, Curtoni ES: Genotyping for cyto-kine polymorphisms: allele frequencies in the Italian population. Eur J Immunogenet 2003; 30:5-10.
10. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a poly-morphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-3199.
11. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
12. Pravica V, Perrey C, Stevens A, Lee JH, Hutchinson IV: A single nucleotide poly-morphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA micro satellite marker of high IFN-gamma production. Hum Immunol 2000;61:863-866.
13. Huang DR, Zhou YH, Xia SQ, Liu L, Pir-skanen R, Lefvert AK: Markers in the pro-moter region of interleucin 10 gene in myas-fhenia gravis: implications of diverse effects of IL-10 in the pathogenesis of the disease. J Neuroimmunol 1999;94:82-87.
14. Verjans GM, Brinkman BM, Van Doornik CE, Kijlstra A, Verweij CL: Polymorphism of tumor necrosis factor-alpha (TNF-alpha) at position -308 in relation to ankylosing spon-dylitis. ClinExp Immunol 1994;97:45-47.
15. Zabaleta J, Schneider BG, Ryckman K, Hooper PF, Camargo MC, Piazuelo MB, Sierra RA, Fontham ET, Correa P, Williams SM, Ochoa AC: Ethnic differences in cyto-kine gene polymorphisms: potential implica-tions for cancer development. Cancer Immu-nol Immunother 2008;57:107-114.
16. Hutchinson IV, Pravica V, Perrey C, Sinnott P: Cytokine gene polymorphisms and rel-evance to forms of rejection. Transplant Proc 1999;31:734-736.
17. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-2147.
18. Hart PH, Ahern MJ, Smith MD, Finlay-Jones JJ: Comparison of the suppressive effects of interleukin-10 and interleukin-4 on syno-vial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Im-munology 1995;84:536-542.
19. Wang W, Bergh A, Damber JE: Chronic in-flammation in benign prostate hyperplasia is associated with focal upregulation of cyclo-oxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate 2004 ;61:60 -72.
20. Wang L, Yang JR, Yang LY, Liu ZT: Chronic inflammation in benign prostatic hyperplasia: Implications for therapy. Med Hypotheses 2008;70:1021-1023.
21. Royuela M, de Miguel MP, Ruiz A, Fraile B, Arenas MI, Romo E, Paniagua R: Interferon-gamma and its functional receptors overex-pression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression. Eur Cytokine Netw 2000;11:119-127.
22. Hobeika AC, Etienne W, Cruz PE, Subrama-niam PS, Johnson HM: IFN-gamma induc-tion of p21WAFl in prostate cancer cells: role in cell cycle, alteration of phenotype and invasive potential. Int J Cancer 1998;77:138-145.
23. Carbonari M, Tedesco T, Del Porto P, Pagan-elli R, Fiorilli M: Human T cells with a type-2 cytokine profile are resistant to apoptosis induced by primary activation: consequences for immunopathogenesis. Clin Exp Immunol 2000;120:454-462.
24. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A: IL-10 inhibits cyto-kine production by activated macrophages. J Immunol 1991;147:3815-3822.
25. Huang S, Ullrich SE, Bar-Eli M: Regulation of tumor growth and metastasis by interleu-kin-10: the melanoma experience. J Interfer-on Cytokine Res 1999;19:697-703.
26. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, Gentilim O, Braga M: Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 1996; 104:1-5.
27. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, AlbertsenPC, Laudone VP, Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol 1997;157:2329 -2333.
28. Stearns ME, Rhim J, Wang M: Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimula-tion of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 1999;5:189-196.
29. Kundu N, Fulton A: Interleukin-10 inhib-its tumor metastasis, down regulates MHC class I, and enhances NK lysis. Cell Immunol 1997;180:55-61.
30. Howell WM, Turner SJ, Bateman AC, Theaker JM: IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001;2: 25-31.
31. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni JF Jr, Chow WH: Increased risk of noncardia gastric cancer associated with pro-inflammatory cytokine gene polymorphisms. Gastroenterology 2003;124:1193-1201.
32. Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA, Pandha HS: An interleukin-10 promoter polymorphism may influence tumor development in renal cell carcinoma. J Urol 2005;173:709-712.
33. Nikolova PN, Pawelec GP, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS, Naumova EJ: As-sociation of cytokine gene polymorphisms with malignant melanoma in Caucasian pop-ulation. Cancer Immunol Immunother 2007; 56:371-379.